Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Rectal Neoplasms 1HIV Infections 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Specimen Handling 265Magnetic Resonance Spectroscopy 216pembrolizumab 212Carboplatin 173Biopsy 162Cisplatin 155Nivolumab 147Cyclophosphamide 131Paclitaxel 116Radiotherapy 115Gemcitabine 110Bevacizumab 91durvalumab 84Dexamethasone 79Rituximab 74Oxaliplatin 71atezolizumab 67Fluorouracil 66Doxorubicin 65Capecitabine 65Docetaxel 64venetoclax 63Etoposide 63Radiosurgery 58Radiation 57Prednisone 55Ipilimumab 55Cytarabine 55Pemetrexed 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Sentinel Lymph Node Biopsy × 90 days × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡